ARPIs reimbursed for mHSPC | Urologists take note!

With approvals and reimbursement increasing all the time for the use of AR pathway inhibitors (ARPIs) in metastatic hormone-sensitive prostate cancer (mHSPC), we chat today about how front-line clinicians need to make sure we are making the most of these opportunities for our patients. Urologists in particular are the clinicians who most frequently diagnose men with metastatic prostate cancer, and who therefore need to be aware of the changing opportunities to improve outcomes for our patients.

Today in this Themed Episode supported by our Gold Partner, Janssen, we chat with Professor Fred Saad, Chair and Professor of Urology at the University of Montreal, who says it is "unethical to treat newly diagnosed metastatic prostate cancer with ADT alone"! We are also joined by Dr Ciara Conduit, Medical Oncologist at Peter MacCallum Cancer Centre, who helps us understand management options for these patients.

Also available as a classic audio podcast in all the usual places